Identificador: TDX:3078
Autores: Martin González, Miguel
Resumen:
Obesity is defined as an excess of fat accumulation that represents a risk to health. It frequently occurs concurrently with other metabolic risk factors related to metabolic syndrome (MetS), such as dyslipidaemia, insulin resistance or non-alcoholic fatty liver disease (NAFLD). Many food bioactive compounds have been identified and further investigated for their ability to prevent obesity and its metabolic associated pathologies. Among them, conjugated linoleic acid (CLA) is one of the dietary bioactive compounds most investigated for weight management, although controversial metabolic results have been reported. However, the use of a single family of bioactive compounds could not be sufficient to correct multisystemic and highly regulated situations such as obesity and its associated metabolic pathologies. Thus, the aim of this Thesis was to evaluate whether the simultaneous co-administration of different bioactive compounds, including CLA, a mixture of grape-seed proanthocyanidins and berry anthocyanins, and the protein hydrolysate from chicken feet Hpp11, could reduce obesity and its associated cardiometabolic risk factors in a much more effective way than its individual administration. Our results demonstrated that the administration of an equal ratio of the CLA isomers c9,t11 and t10,c12 at low doses caused a decrease in the body weight gain induced by a cafeteria diet, and improved other cardiometabolic risk factors, without presenting any CLA-related adverse effects. In addition, the body weight lowering effect of CLA was higher when it was co-administrated with the chicken feet hydrolysate Hpp11 and a mixture of proanthocyanidins and anthocyanidins. This anti-obesity effect, which could be mediated by an improvement of hypothalamic leptin sensitivity, was also not accompanied by any adverse effect of weight loss. On the contrary, MIX produced an improvement on glucose and lipid metabolism and exhibited antihypertensive properties. Thus, MIX could be a good candidate to be used as nutraceutical or to be included in functional foods for the management of metabolic syndrome.